Advanced

Behandling med anti-TNF-alfa- effektivt komplement vid spondylartropati

Mandl, Thomas LU and Jacobsson, Lennart LU (2002) In Läkartidningen 99(51-52). p.93-5189
Abstract
Nine patients with spondylarthropathy (SpA) (6 with ankylosing spondylitis and 3 with psoriatic arthritis) who had not responded properly to conventional DMARD therapy were treated with 3 infusions (at 0, 2 and 6 weeks) of the TNF alpha inhibitor infliximab (3 mg/kg), in combination with methotrexate. To measure the effect of treatment, patients were evaluated before as well as 8 and 12 weeks after treatment with respect to disease activity (BASDAI), function (BASFI), mobility (BASMI) and global well-being in the past week (BASG1) as well as the past 6 months (BASG2). BASDAI, BASFI, BASMI and BASG1 improved significantly, with the most pronounced effect during the first 8 weeks. Also, ESR and CRP decreased significantly from baseline to 12... (More)
Nine patients with spondylarthropathy (SpA) (6 with ankylosing spondylitis and 3 with psoriatic arthritis) who had not responded properly to conventional DMARD therapy were treated with 3 infusions (at 0, 2 and 6 weeks) of the TNF alpha inhibitor infliximab (3 mg/kg), in combination with methotrexate. To measure the effect of treatment, patients were evaluated before as well as 8 and 12 weeks after treatment with respect to disease activity (BASDAI), function (BASFI), mobility (BASMI) and global well-being in the past week (BASG1) as well as the past 6 months (BASG2). BASDAI, BASFI, BASMI and BASG1 improved significantly, with the most pronounced effect during the first 8 weeks. Also, ESR and CRP decreased significantly from baseline to 12 weeks after treatment. We conclude that infliximab is an effective therapy in SpA which does not respond sufficiently to conventional DMARD therapy. Best response to treatment was found after the first treatment regimen with regard to both effect and effect duration. Most patients responding to and tolerating anti-TNF alpha treatment needed one infliximab infusion every 8th week (3 mg/kg) to control disease activity and symptoms. Further studies are warranted to evaluate long-term outcome of anti-TNF alpha treatment in patients with SpA. (Less)
Please use this url to cite or link to this publication:
author
organization
alternative title
Anti-TNF-alpha treatment--an effective complement in spondyloarthropathy
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Spondylitis, Recurrence, Middle Age, Methotrexate: administration & dosage, Ankylosing: immunology, Tumor Necrosis Factor: antagonists & inhibitors, Treatment Outcome, Tumor Necrosis Factor: immunology, English Abstract, Combination, Ankylosing: drug therapy, Human, Follow-Up Studies, Male, Female, Psoriatic: immunology, Drug Therapy, Psoriatic: drug therapy, Arthritis, Monoclonal: administration & dosage, Antirheumatic Agents: administration & dosage, Adult, Antibodies
in
Läkartidningen
volume
99
issue
51-52
pages
93 - 5189
publisher
Swedish Medical Association
ISSN
0023-7205
language
Swedish
LU publication?
yes
id
95c776b4-05d5-47e9-8874-ee78dc12dec2 (old id 114449)
alternative location
http://ltarkiv.lakartidningen.se/artNo25935
date added to LUP
2007-07-26 10:47:26
date last changed
2016-04-16 04:16:01
@article{95c776b4-05d5-47e9-8874-ee78dc12dec2,
  abstract     = {Nine patients with spondylarthropathy (SpA) (6 with ankylosing spondylitis and 3 with psoriatic arthritis) who had not responded properly to conventional DMARD therapy were treated with 3 infusions (at 0, 2 and 6 weeks) of the TNF alpha inhibitor infliximab (3 mg/kg), in combination with methotrexate. To measure the effect of treatment, patients were evaluated before as well as 8 and 12 weeks after treatment with respect to disease activity (BASDAI), function (BASFI), mobility (BASMI) and global well-being in the past week (BASG1) as well as the past 6 months (BASG2). BASDAI, BASFI, BASMI and BASG1 improved significantly, with the most pronounced effect during the first 8 weeks. Also, ESR and CRP decreased significantly from baseline to 12 weeks after treatment. We conclude that infliximab is an effective therapy in SpA which does not respond sufficiently to conventional DMARD therapy. Best response to treatment was found after the first treatment regimen with regard to both effect and effect duration. Most patients responding to and tolerating anti-TNF alpha treatment needed one infliximab infusion every 8th week (3 mg/kg) to control disease activity and symptoms. Further studies are warranted to evaluate long-term outcome of anti-TNF alpha treatment in patients with SpA.},
  author       = {Mandl, Thomas and Jacobsson, Lennart},
  issn         = {0023-7205},
  keyword      = {Spondylitis,Recurrence,Middle Age,Methotrexate: administration & dosage,Ankylosing: immunology,Tumor Necrosis Factor: antagonists & inhibitors,Treatment Outcome,Tumor Necrosis Factor: immunology,English Abstract,Combination,Ankylosing: drug therapy,Human,Follow-Up Studies,Male,Female,Psoriatic: immunology,Drug Therapy,Psoriatic: drug therapy,Arthritis,Monoclonal: administration & dosage,Antirheumatic Agents: administration & dosage,Adult,Antibodies},
  language     = {swe},
  number       = {51-52},
  pages        = {93--5189},
  publisher    = {Swedish Medical Association},
  series       = {Läkartidningen},
  title        = {Behandling med anti-TNF-alfa- effektivt komplement vid spondylartropati},
  volume       = {99},
  year         = {2002},
}